EPA:ALVAL - Euronext Paris - Matif - FR0013254851 - Common Stock - Currency: EUR
EPA:ALVAL (5/8/2025, 7:00:00 PM)
1.1622
+0.04 (+3.21%)
The current stock price of ALVAL.PA is 1.1622 EUR. In the past month the price increased by 14.12%. In the past year, price decreased by -74.68%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
1ABBV.MI | ABBVIE INC | 18.28 | 294.00B | ||
4AB.DE | ABBVIE INC | 18.06 | 290.47B | ||
AMG.DE | AMGEN INC | 13.13 | 129.73B | ||
1GILD.MI | GILEAD SCIENCES INC | 12.71 | 108.39B | ||
GIS.DE | GILEAD SCIENCES INC | 12.69 | 108.25B | ||
VX1.DE | VERTEX PHARMACEUTICALS INC | 1471.92 | 98.38B | ||
ARGX.BR | ARGENX SE | 107.09 | 30.99B | ||
22UA.DE | BIONTECH SE-ADR | N/A | 20.33B | ||
IDP.DE | BIOGEN INC | 7.5 | 15.39B | ||
0QF.DE | MODERNA INC | N/A | 8.48B | ||
1MRNA.MI | MODERNA INC | N/A | 8.14B | ||
BIO.DE | BIOTEST AG | 65.54 | 1.69B |
Valbiotis SA engages in the products and candidate drugs designed to prevent metabolic diseases. The company is headquartered in Perigny, Nouvelle-Aquitaine. The company went IPO on 2017-06-07. The firm specializes in developing nutrition solutions designed to prevent cardiometabolic diseases and provide nutritional support for patients. The company seeks to develop solutions designed to prevent type 2 diabetes, NASH, (non-alcoholic steatohepatitis) and obesity and to offer nutritional support. The firm prevents disease by developing products that reduce the risk factors of irreversible chronic diseases. The company provides patient support through new-generation medical nutrition solutions containing patented substances with clinically proven effects. Its products are plant-based and undergo strict scientific and clinical tests in collaboration with academic research centers.
VALBIOTIS SAS
12F rue Paul Vatine
Perigny NOUVELLE-AQUITAINE FR
Employees: 44
The current stock price of ALVAL.PA is 1.1622 EUR. The price increased by 3.21% in the last trading session.
The exchange symbol of VALBIOTIS SAS is ALVAL and it is listed on the Euronext Paris - Matif exchange.
ALVAL.PA stock is listed on the Euronext Paris - Matif exchange.
11 analysts have analysed ALVAL.PA and the average price target is 3.67 EUR. This implies a price increase of 215.95% is expected in the next year compared to the current price of 1.1622. Check the VALBIOTIS SAS stock analysts ratings, price target forecast and up-and down grades for more detailed information.
VALBIOTIS SAS (ALVAL.PA) has a market capitalization of 18.49M EUR. This makes ALVAL.PA a Nano Cap stock.
VALBIOTIS SAS (ALVAL.PA) currently has 44 employees.
VALBIOTIS SAS (ALVAL.PA) has a support level at 0.99 and a resistance level at 1.38. Check the full technical report for a detailed analysis of ALVAL.PA support and resistance levels.
The Revenue of VALBIOTIS SAS (ALVAL.PA) is expected to decline by -96.57% in the next year. Check the estimates tab for more information on the ALVAL.PA EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ALVAL.PA does not pay a dividend.
VALBIOTIS SAS (ALVAL.PA) will report earnings on 2025-10-27.
VALBIOTIS SAS (ALVAL.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.66).
ChartMill assigns a technical rating of 1 / 10 to ALVAL.PA. When comparing the yearly performance of all stocks, ALVAL.PA is a bad performer in the overall market: 97.24% of all stocks are doing better.
ChartMill assigns a fundamental rating of 3 / 10 to ALVAL.PA. The financial health of ALVAL.PA is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months ALVAL.PA reported a non-GAAP Earnings per Share(EPS) of -0.66. The EPS increased by 22.69% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -34.58% | ||
ROE | -53.12% | ||
Debt/Equity | 0.24 |
ChartMill assigns a Buy % Consensus number of 85% to ALVAL.PA. The Buy consensus is the average rating of analysts ratings from 11 analysts.
For the next year, analysts expect an EPS growth of -4.38% and a revenue growth -96.57% for ALVAL.PA